SCHEMBL23699088

SCHEMBL23699088

O=C(Nc1ccc2c(c1)OCO2)N1CC2(CC(Oc3ccnc4ccc(F)cc34)C2)C1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 19/20 0.49
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32674623 1.00 IDO1 (0.49) IDO1NPC1MAPTRAB9A
SCHEMBL23699151 0.95 IDO1 (0.49) IDO1MAPT
SCHEMBL23699078 0.89 IDO1 (0.60) IDO1
SCHEMBL23699081 0.88 IDO1 (0.47) IDO1
SCHEMBL23707502 0.87 MAPT (0.52) IDO1NPC1MAPTRAB9A
SCHEMBL21835126 0.85 IDO1 (0.61) IDO1
SCHEMBL23699161 0.84 IDO1 (0.55) IDO1
SCHEMBL23699145 0.83 GRIN2B (0.50) IDO1
SCHEMBL23707416 0.82 SMN1; SMN2 (0.52) IDO1MAPTRAB9A
SCHEMBL23699105 0.79 IDO1 (0.49) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2026-02-17 US disclosed
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2021-12-09 US disclosed
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2021-12-09 US disclosed
EP-3858813-A1 QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2021-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity IDO2, IDO1, HDAC2 IDO1 2/4885NPC1 2783/4885MAPT 3547/4885
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY IDO1, IDO2, INMT IDO1 1/4885NPC1 4031/4885MAPT 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.